European Society of Cell and Gene Therapy, October 25-28, 2013

European Society of Cell and Gene Therapy. To register: http://www.esgct.eu

Lysogene press release: August 09, 2013, Paris, France- Sanfilippo Syndrome – or MPSIII – is a rare and lethal neurological disease.

LYSOGENE is the sole clinical stage biotechnology company in Sanfilippo Syndrome worldwide. SAF-301 AAV gene therapy product developed by Lysogene has recently undergone a successful clinical trial in four young patients affected with the disease (France). Preliminary data collected during the clinical trial support an excellent safety profile from a product and a surgery perspective, as well as very promising exploratory efficacy data. Full data are planned to be presented by the principal investigator Professor Marc Tardieu (Head of Unit, Neuropediatry, APHP, CHU Bicêtre, Le Kremlin-Bicêtre (France), during the annual meeting of the ESCGT (European Society of Cell and Gene Therapy) to be held October 25-28, 2013, in Madrid, Spain.

For the complete press release go to: http://www.lysogene.com